[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antimicrobial-resistance-amr\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antimicrobial-resistance-amr":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,73,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100571234","pkpd-relationship-of-cazavi-and-fos-in-the-treatment-of-patients-with-infections-due-to-cre-100571234",false,"NCT06717594","PK\u002FPD Relationship of CAZ\u002FAVI and FOS in the Treatment of Patients With Infections Due to CRE","PK\u002FPD Relationship of CAZ\u002FAVI and FOS in the Treatment of Patients With Infections Due to Carbapenem-resistant Enterobacterales (CRE)","CAVIFOS","Inclusion Criteria:\n\n* Signature of the informed consent\n* Age ≥ 18 years\n* Adult patients treated for ≥ 48 hours with CAZ\u002FAVI or CAZ\u002FAVI plus FOS for a microbiologically documented CRE infection\n\nExclusion Criteria:\n\n* Polymicrobial\u002Fmixed infections with exception of cases with multiple Enterobacterales susceptible to study drugs","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","A multicenter international prospective observational pharmacological study in adult patients (≥18 years) treated with ceftazidime\u002Favibactam (CAZ\u002FAVI) alone or with CAZ\u002FAVI plus fosfomycin (FOS) for infection due to carbapenem-resistant Enterobacterales (CRE) (KPC and\u002For OXA-48).",[25,26],"Gram Negative Infections","Antimicrobial Resistance (AMR)",[28,29,30,31,32],"Gram negative infection","Ceftazidime\u002FAvibactam","Fosfomycin","Pharmacokinetics\u002FPharmacodynamics targets","Carbapenem-resistant Enterobacterales (CRE)","RECRUITING","2026-06-11",{"date":36,"type":37},"2026-06-12","ACTUAL",{"date":39,"type":37},"2023-12-01",{"date":41,"type":21},"2026-12-31",{"name":43,"class":44},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100623182","development-and-implementation-of-mobile-antibiograms-to-optimize-empirical-antibiotic-prescriptions-among-prescribers-in-tertiary-hospitals-in-tanzania-100623182","NCT07393308","Development and Implementation of Mobile Antibiograms to Optimize Empirical Antibiotic Prescriptions Among Prescribers in Tertiary Hospitals in Tanzania","Enhancing the Optimization of Empirical Antibiotic Therapy: Development and Implementation of Mobile Antibiograms in Tertiary Hospitals in Tanzania","AMR; AMU; DDD","Inclusion criteria\n\n1. All prescribers working in the selected tertiary referral hospitals\n2. All prescribers owning smartphones\n3. Prescribers who consent to take part in the study\n\nExclusion criteria\n\n1\\. Temporarily employed prescribers",true,{"count":56,"type":21},300,"INTERVENTIONAL",[59],"NA","Antimicrobial resistance (AMR) is a critical issue, especially in Africa, with resistance to common antibiotics reaching 100% in some areas. In Tanzania, limited access to culture tests and antibiograms forces healthcare providers to rely on experience for prescribing, heightening AMR risks. This study aims to determine the effectiveness of mobile antibiograms in optimizing empirical antibiotic therapy in tertiary hospitals in Tanzania.",[62,26],"Antimicrobial Prescribing Practices","NOT_YET_RECRUITING","2026-01-30",{"date":66,"type":37},"2026-02-06",{"date":68,"type":21},"2026-02-01",{"date":70,"type":21},"2028-06-30",{"name":72,"class":44},"Muhimbili University of Health and Allied Sciences",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100440628","nccr-antiresist-new-approaches-to-combat-antibiotic-resistant-bacteria-100440628","NCT05017766","NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria","NCCR AntiResist: Mono-center Study to Identify New Approaches to Combat Antibiotic-resistant Bacteria.","AntiResist","Inclusion Criteria:\n\n* Patients with confirmed (i) urinary tract infection, (ii) pneumonia (including patients after lung transplantation, cystic fibrosis) or (iii) deep-seated infection with focus pathogen:\n\n  * E. coli\n  * Klebsiella species\n  * S. aureus\n  * P. aeruginosa\n* Controls: no detectable bacteria in routine microbiology lab and no other infection site at inclusion of the sample and follow up for 10 days, signed general consent\n* Clinical controls without obtained samples, but with confirmed (i) urinary tract infection, (ii) pneumonia (including patients after lung transplantation, cystic fibrosis) or (iii) deep-seated infection with focus pathogen:\n\n  * E. coli\n  * Klebsiella species\n  * S. aureus\n  * P. aeruginosa\n\nExclusion Criteria:\n\n* Patients who have refused research and reuse of their data\u002Fsamples (e.g. general consent) or any other decline (e.g. Patientenverfügung).\n* other than one of the focus bacteria in routine microbiology lab\n* Age: \\\u003C18 years\n* Controls without signed general consent",{"count":82,"type":21},8000,"This is an explorative, mono-center study including prospectively collected patient samples from the University Hospital of Basel. It is to investigate antimicrobial resistance (AMR) including three clinical manifestations of infectious diseases: urinary tract infection, pneumonia and deep-seated infections. The focus is on four bacteria (E. coli, Klebsiella species, S. aureus, P. aeruginosa) that are part of the high priority list of World Health Organization (WHO). Residual patient samples are analysed for proteomic, metabolomic and transcriptomic analysis, immunocytochemical or fluorescence in-situ hybridisation (FISH) analysis, flow cytometry analysis (FACS) and immunophenotyping and exploration of bacterial properties.",[26],[86,87,88,89,90,91,92,93,94,95,96,97,98],"National Center of Competence in Research (NCCR)","Urinary tract infection (UTI)","Pneumonia","Deep-seated infections","E. coli","Klebsiella species","S. aureus","P. aeruginosa","bacterial properties","Community-acquired pneumonia (CAP)","Hospital-acquired pneumonia (HAP)","Ventilator-associated pneumonia (VAP)","cystic fibrosis (CF)","2025-02-27",{"date":101,"type":37},"2025-03-04",{"date":103,"type":37},"2020-12-03",{"date":105,"type":21},"2028-12",{"name":107,"class":44},"University Hospital, Basel, Switzerland",1,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":54,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100566120","pkpd-analysis-of-ceftazidimeavibactam-or-cefiderocol-with-or-without-fosfomycin-for-the-treatment-of-difficult-to-treat-gram-negative-infections-100566120","NCT06651047","PK\u002FPD Analysis of Ceftazidime\u002FAvibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections","Pharmacokinetic\u002FPharmacodynamic Analysis of Ceftazidime\u002FAvibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections","PACCOF","Inclusion Criteria:\n\n* Patients with infection due to a difficult-to-treat Gram-negative bacteria treated with CAZ\u002FAVI alone, CEF alone, CAZ\u002FAVI plus FOS, or CEF plus FOS (any age)\n* Signature of the informed consent (for pediatric patients: parents or guardians able to provide consent)\n\nExclusion Criteria:\n\n* Premature newborns\n* Polymicrobial\u002Fmixed infections with the exception of cases with multiple Gram-negative bacteria susceptible to study drugs\n* Continuous renal replacement therapy (CRRT) applications\n\nInclusion Criteria for Healthy Volunteer Subjects:\n\n* Age ≥18 years\n* Signature of the informed consent\n\nExclusion Criteria for Healthy Volunteer Subjects:\n\n\\- Any known clinically relevant health problems",{"count":118,"type":21},120,"A multicenter, national, prospective, observational pharmacological study of patients with difficult-to-treat Gram-negative infections treated with ceftazidime\u002Favibactam (CAZ\u002FAVI) or cefiderocol (CEF) monotherapy or combination therapy with ceftazidime\u002Favibactam associated with fosfomycin (FOS) or cefiderocol associated with fosfomycin.",[121,26],"Gram Negative Infection",[123,29,124,30,31,32],"Gram-negative infection","Cefiderocol","2024-10-18",{"date":127,"type":37},"2024-10-21",{"date":129,"type":37},"2024-07-09",{"date":131,"type":21},"2025-09-30",{"name":133,"class":44},"University of Bologna",11]